CFL1P2 as A Potential Drug Target for Neurological Disorders (G391039)

Target Name: CFL1P2

NCBI ID: G391039

CFL1P2

Other Name(s): CFLL2 | CFLP2 | cofilin 1 pseudogene 2 | Cofilin 1 pseudogene 2

CFL1P2 as A Potential Drug Target for Neurological Disorders

CFL1P2 (CFLL2), a protein found in the cerebral cortical granule cells, has been identified as a potential drug target (or biomarker) for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The cerebral cortical granule cells, also known as extrapyramidal cells, are a type of nerve cell located in the outer layer of the brain that plays a crucial role in motor function, decision-making, and other cognitive processes. However, as individuals age, these cells begin to die off, leading to the development of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

CFL1P2 is a transmembrane protein that is expressed in the cerebral cortical granule cells and is involved in the formation and maintenance of the granule cell lineage. It has been shown to play a role in the regulation of neuronal excitability and in the development of neurodegenerative disorders.

Research has suggested that changes in the expression of CFL1P2 may be a key factor in the development of neurodegenerative disorders. For example, studies have shown that CFL1P2 levels are reduced in the brains of individuals with Alzheimer's disease and that these levels are associated with the severity of the disease.

Additionally, alterations in CFL1P2 expression have also been observed in the brains of individuals with Parkinson's disease, a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain.

The potential drug targets for CFL1P2 include small molecules, such as those that can modulate its expression or activity, as well as antibodies that can target the protein itself. Researchers are also exploring the use of CFL1P2 as a biomarker to diagnose and monitor the progression of neurodegenerative disorders.

One approach to targeting CFL1P2 is to use small molecules that can modulate its expression or activity. One such compound is called CFL1P2 inhibitor, which is a drug that has been shown to reduce the expression of CFL1P2 in the brains of individuals with Alzheimer's disease.

Another approach to targeting CFL1P2 is to use antibodies that can specifically target the protein. Researchers have developed antibodies that are designed to bind to CFL1P2 and have shown that these antibodies can label the protein in the brains of individuals with Alzheimer's disease.

While the use of CFL1P2 as a drug target or biomarker is still in its early stages, it holds great promise for the treatment of neurodegenerative disorders. Further research is needed to fully understand the role of CFL1P2 in the development and progression of these disorders and to develop effective treatments.

In conclusion, CFL1P2 is a protein that is expressed in the cerebral cortical granule cells and is involved in the formation and maintenance of the granule cell lineage. Its expression is altered in the brains of individuals with neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. As a result, CFL1P2 is a potential drug target or biomarker for the treatment of these disorders. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: Cofilin 1 Pseudogene 2

The "CFL1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFL1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets